SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-026746
Filing Date
2022-02-25
Accepted
2022-02-24 17:36:55
Documents
15
Period of Report
2022-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm227665d1_8k.htm   iXBRL 8-K 26282
2 EXHIBIT 99.1 tm227665d1_ex99-1.htm EX-99.1 90648
6 GRAPHIC tm227665d1_ex99-1img008.jpg GRAPHIC 5535
7 GRAPHIC tm227665d1_ex99-1sp2img001.jpg GRAPHIC 13614
  Complete submission text file 0001104659-22-026746.txt   327949

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ymab-20220224.xsd EX-101.SCH 3024
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ymab-20220224_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ymab-20220224_pre.xml EX-101.PRE 22589
9 EXTRACTED XBRL INSTANCE DOCUMENT tm227665d1_8k_htm.xml XML 3596
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 22672989
SIC: 2834 Pharmaceutical Preparations